[en] Oral daily and weekly bisphosphonates represent the current mainstay of treatment for postmenopausal osteoporosis (PMO). However, the inconvenience of frequent dosing is known to negatively affect adherence to therapy in the long term. This has prompted the development of convenient oral bisphosphonate regimens that feature simple, less frequent dosing schedules. Such regimens require high potency agents, which can be given at low effective doses and that also have good tolerability. Ibandronate is a potent, nitrogen-containing bisphosphonate with proven efficacy when given intermittently to estrogen-depleted beagle dogs, rats and cynomolgus monkeys. Clinically, a pivotal prospective study has established that oral ibandronate has significant vertebral fracture efficacy in PMO, whether given daily (2.5 mg) or intermittently (20 mg every other day for 12 doses every 3 months; extended between-dose interval > 2 months). Both oral regimens were well tolerated, which is noteworthy as patients with a history of gastrointestinal (GI) disturbance were not specifically excluded. As a result of these findings, a large, multinational, randomized, double-blind study (Monthly Oral iBandronate In LadiEs: MOBILE) is currently exploring the non-inferiority of once-monthly oral ibandronate (100 or 150 mg) to the oral daily ibandronate (2.5 mg) regimen with proven anti-fracture efficacy, in terms of lumbar spine bone mineral density (BMD) change. As with the trials investigating the weekly administration of other bisphosphonates, vertebral fracture efficacy will be inferred if the study demonstrates the non-inferiority of once-monthly ibandronate to the proven oral daily regimen in terms of spinal BMD change. The availability of this once-monthly ibandronate regimen is expected to offer benefits in terms of convenience (by having to follow dosing recommendations once a month vs. once daily or weekly) and potentially tolerability (by reducing the potential for upper GI irritation that can result from frequent, repeated exposure). Greater convenience and tolerability may enhance the therapy adherence and, hence, improve long-term therapeutic outcomes in PMO.
Disciplines :
Endocrinology, metabolism & nutrition
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA 280:2077-2082
Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon M, Melton LJ (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001-1005
Cumming RG, Nevitt MC, Cummings SR (1997) Epidemiology of hip fractures. Epidemiol Rev 19:244-257
Sernbo I, Johnell O (1993) Consequences of a hip fracture: a prospective study over 1 year. Osteoporos Int 3:148-153
Beatriz JE, Perry HM (1994) Age-related osteoporosis. Clin Geriatr Med 10:575-577
Gold DT, Lyles KW, Shipp KM, Drezner MK (2001) Osteoporosis and its nonskeletal consequences: their impact on treatment decisions. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis, 2nd edn. Academic Press, San Diego, pp 4779-4784
Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM Hay SM, Hosking DJ, Purdie DW, Ralston SH, Reeve J, Russell RG, Stevenson JC (2001) Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action? QJM 94:575-597
Johnell O (1997) The socioeconomic burden of fractures: today and in the 21st century. Am J Med 103:20S-26S
Cooper C, Campion G, Melton LJ (1992) Hip fractures in the elderly: a worldwide projection. Osteoporos Int 2:285-289
Miller NH (1997) Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 102:43-49
Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209-216
Hamilton B, McCoy K, Taggert H (2003) Tolerability and compliance with risedronate in clinical practice. Osteoporos Int 14:259-262
Lombas C, Hakim C, Zanchetta JR (2000) Compliance with alendronate treatment in an osteoporosis clinic. J Bone Miner Res 15 [Suppl 1]:M406
Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209-216
Eastell R, Garnero P, Vrijens B (2003) Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study (abstract P-297). Calcif Tissue Int 72:408
Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965-968
Caro J, Isak KJ, Huybrechts KF (2003) Clinical and economic impact of adherence to osteoporosis medication (abstract PL6). Osteoporos Int 14 [Suppl 7]:S2-S3
Papapoulos SE (2001) Bisphosphonates in the management of postmenopausal osteoporosis. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis, 2nd edn. Academic Press, New York, pp 631-649
Mersfelder T Armitstead JA, Ivey MF, Cedars M (1999) A medication use evaluation of alendronate: compliance with administration guidelines. Pharm Pract Manag Q 18:10-58
Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Ther 23:1296-1310
Rizzoli R, Greenspan SL, Bone G, Schnitzer TJ, for the Alendronate Once-Weekly Study Group (2002) Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis. J Bone Miner Res 17:1988-1996
Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC 2nd, Kaur A, Thompson DE, Yates J, Orloff JJ (2000) Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano) 12:1-12
Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R (2002)The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71:103-111
Simon JA, Lewiecki M, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter randomized open-label, crossover study. Clin Ther 24:1871-1886
Kendler D, Kung AWC, Fuleihan GE, Gonzalez Gonzalez JG, Gaines KA, Verbruggen N, Melton ME (2004) Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48:243-251
Recker RR, Gallagher R, Amonkar M, Smith JC, MacCosbe PE (2004) Medication persistence is better with weekly bisphosphonates, but it remains suboptimal (abstract SA407). J Bone Miner Res 19 [Suppl 1]:S172
Cramer JA, Amonkar MM, Hebborn A, Suppapanya N (2004) Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women (abstract M434)? J Bone Miner Res 19 [Suppl 1]:S448
Bartl R, Goette S, Hadji P, Hammerschmidt T (2005) Persistence and compliance with daily- and weekly-administered bisphosphonates in German women with osteoporosis ECCEO 2005 (Poster P195)
Cooper C, Emkey RD, McDonald RH, Hawker G, Bianchi G, Wilson K, Schimmer RC (2003) Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 88:4609-4615
Peter CP, Handt LK, Smith SM (1998) Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci 43:1998-2002
Bone HG, Adami S, Rizzoli R, Favus M, Ross PD, Santora A, Prahalada S, Daifotis A, Orloff J, Yates J (2000) Weekly administration of alendronate: rationale and plan for clinical assessment. Clin Ther 22:15-28
Karam SM (1999) Lineage commitment and maturation of epithelial cells in the gut. Front Biosic 4:D286-D298
Bauss F, Russell RGG (2004) Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int 15:423-433
Leu C, Rodan GA, Reszka AA (2003) Relative binding affinities of bisphosphonates for human bone (abstract). J Bone Miner Res 18 [Suppl 2]:S374
Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PH, Hamdy NA, Landman JO, McCloskey EV, Netelenbos JC, Pauwels EK, Roos JC, Valentijn RM, Zwinderman AH (2002) Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension. J Bone Miner Res 17:1057-1064
Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249
Reginster J-Y, Christiansen C, Roux C, Fechtenbaum J, Rouillon A, Tou KP (2001) Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporos Int 12:169-177
Mühlbauer RC, Bauss F, Schenk R, Janner M, Bosies E, Strein K, Fleisch H (1991) BM21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003-1011
Green JF (2001) Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Semin Oncol 28 [Suppl 6]:4-10
Bauss F (1997) Ibandronate in malignant bone diseases and osteoporosis - preclinical results. Onkologie 20:204-208
Delmas PD, Recker RR, Chesnut CH III (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 15:792-798
Reginster J-Y (submitted) Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review. Curr Pharm Des
Schimmer RC, Bauss F (2003) Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies. Clin Ther 25:19-34
World Health Organization (1998) Guidelines for the preclinical evaluation and clinical trials in osteoporosis. WHO, Geneva
Bauss F, Lalla S, Endele R, Hothorn (2002a) Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol 29:2200-2208
Bauss F, Wagner M, Hothorn LH (2002b) Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. J Rheumatol 29:990-998
Fleisch H (1996) The bisphosphonate ibandronate, given daily as well as discontinuously, decreases bone resorption and increases calcium retention as assessed by 45Ca kinetics in the intact rat. Osteoporos Int 6:166-170
Lalla S, Hothorn LA, Haag N, Bader R, Bauss F (1998) Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporos Int 8:97-103
Monier-Faugere MC, Geng Z, Paschalis EP, Qi Q, Arnala I, Bauss F, Boskey AL, Malluche HH (1999) Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res 14:1768-1778
Smith SY, Recker RR, Hannan M, Müller R, Bauss F (2003) Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32:45-55
Müller R, Hannan MK, Smith SY, Bauss F (in press) Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. J Bone Miner Res
Monier-Faugere MC, Friedler RM, Bauss F, Malluche HH (1993) A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 8:1345-1355
Delmas PD, Emkey R, Gilbride J, Schimmer RC, Leishman B, Rosen CJ (2003) Oral ibandronate has a similar gastrointestinal (GI) safety profile to placebo in patients with a history of GI disorders or receiving concomitant NSAIDs (abstract P267). Osteoporos Int 14 [Suppl 7]:S74
Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC 3rd, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 323:73-79
Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 323:1265-1271
Reginster J-Y, Wiese C, Wilson K, Schimmer RC (2003) Monthly oral ibandronate decreases bone turnover in postmenopausal women with low bone mass: results from the Monthly Oral Pilot Study (MOPS) (abstract OC15). Osteoporos Int 14 [Suppl 7]:S5
Geischke R, Hayashi N, Vis P, Jacqmin P (2003) Modelling the effects of ibandronate treatment on the time course of bone mineral density change in osteoporotic postmenopausal women (abstract P-280). Calcif Tissue Int 72:404
Temple RJ (2003) Study designs in osteoporosis. J Bone Miner Res 18:1129-1132
World Medical Association (2000) Declaration of Helsinki: ethical principles for medical research involving human subjects. 52nd World Medical Association General Assembly, 3-7 October 2000, Edinburgh, Scotland
Wasnich RD, Miller PD (2000) Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85:231-236
Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD (2002) Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87:1586-1592
Khosla S (2003) Surrogates for fracture endpoints in clinical trials. J Bone Miner Res 18:1146-1149
Wasnich R, Miller PD, Chesnut CH, Huss H, Wilson K, Schimmer RC (2003) Changes in bone mineral density as a predictor for vertebral fracture efficacy with ibandronate: results from a phase III fracture study (abstract SA353). J Bone Miner Res 18 [Suppl 2]:S160
Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD (2004) Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res 19:394-401
Delmas PD, Calvo G, Boers M, Abadie E, Avouac B, Kahan A, Kaufman JM, Laslop A, Lekkerkerker JF, Nilsson P, Van Zwieten-Boot B, Kreutz G, Reginster JY, Group for the Respect of Ethics and Excellence in Science (GREES) (2002) The use of placebo-controlled and non-inferiority trials for the evaluation of new drugs in the treatment of postmenopausal osteoporosis. Osteoporos Int 13:1-5
Committee for Proprietary Medicinal Products (CPMP) (2000) Points to consider on switching between superiority and non-inferiority. The European Agency for the Evaluation of Medicinal Products, London
Ravn P, Clemmesen B, Riis BJ, Christiansen C (1996) The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1 year, randomised, double-blind, placebo controlled dose finding study. Bone 19:527-533
Riis BJ, Ise J, Von Stein T, Bagger Y, Christiansen C (2001) Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 16:1871-1878
